Citations

Clear

1526 citation(s) found for "Sun, Yu".

Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study
Feng, Tom , Sun, Xizi, Howard, Lauren E. , Vidal, Adriana C. , Gaines, Alexis R., Moreira, Daniel M. , Castro‐Santamaria, Ramiro , Andriole, Gerald L. , Freedland, Stephen J. , Howard, Lauren E

Mayo Clinic

Cancer Prevention Research | September 10, 2015 | Volume: 8 | Issue: 11 | Pages: 1055-1060

10.1158/1940-6207.capr-15-0141 | PMID 26353947 Get It

Abstract The role of metformin in prostate cancer chemoprevention remains unclear. REDUCE, which followed biopsy-negative men with protocol-dictated PSA-independent biopsies at 2- and 4-years, provides an opportunity to evaluate the link between metformin use and prostate cancer diagnosis with minimal confounding from screening biases. In diabetic men from REDUCE, we tested the association between metformin use, use of other antidiabetic medications, versus no antidiabetic medication use, and prostate cancer diagnosis as well as prostate cancer grade (low-grade Gleason 4–6 and high-grade Gleason 7–10) using logistic regression. Of the 540 diabetic men with complete data, 205 (38%) did not report use of any antidiabetic medications, 141 (26%) reported use of at least one antidiabetic medication other than metformin, and 194 (36%) reported use of metformin. During the 4-year study, 122 men (23%) were diagnosed with prostate cancer. After adjusting for various clinical and demographic characteristics, we found that metformin use was not significantly associated with total (OR, 1.19; P = 0.50), low- (OR, 1.01; P = 0.96), or high-grade (OR, 1.83; P = 0.19) prostate cancer diagnosis. Likewise, there was no significant association between the use of non-metformin antidiabetic medications and prostate cancer risk in both crude (OR, 1.02; P = 0.95) and multivariable analysis (OR, 0.85; P = 0.56). Furthermore, the interactions between antidiabetic medication use and BMI, geographic location, coronary artery disease, smoking, and treatment group were not significant (all P > 0.05). Among diabetic men with a negative prestudy biopsy who all underwent biopsies largely independent of PSA, metformin use was not associated with reduced risk of prostate cancer diagnosis. Cancer Prev Res; 8(11); 1055–60. ©2015 AACR.
Human umbilical cord blood‐derived mesenchymal stem cells improve functional recovery through thrombospondin1, pantraxin3, and vascular endothelial growth factor in the ischemic rat brain
Moon, Hyo‐Eun, Kim, Hye‐Soo R., Paek, Seung Leal, Kim, Yona , Chang, Jong Wook , Yang, Yoon Sun , Kim, Kwanwoo , Hwang, Jae Ha , Kim, Dong Gyu , Paek, Sun Ha , Park, Hyung Woo , Moon, Hyo-Eun, Oh, Wonil , Kim, Jin‐Wook

Mayo Clinic

Journal of Neuroscience Research | September 2, 2015 | Volume: 93 | Issue: 12 | Pages: 1814-1825

10.1002/jnr.23616 | PMID 26332684 Get It

Cell therapy is a potential therapeutic method for cerebral ischemia, which remains a serious problem. In the search for more effective therapeutic methods, many kinds of stem cells from various tissues have been developed and tested as candidate therapeutic agents. Among them, human umbilical cord blood (hUCB)‐derived mesenchymal stem cells (MSCs) are widely used for cell therapy because of their genetic flexibility. To confirm that they are effective and understand how they affect ischemic neural cells, hUCB‐MSCs were directly administered ipsilaterally into an ischemic zone induced by middle cerebral artery occlusion (MCAO). We found that the neurobehavioral performance of the hUCB‐MSC group was significantly improved compared with that of the vehicle‐injected control group. The infarct was also remarkably smaller in the hUCB‐MSC group. Additionally, hUCB‐MSC transplantation resulted in a greater number of newly generated cells and angiogenic and tissue repair factors and a lower number of inflammatory events in the penumbra zone. To determine why these events occurred, hUCB‐MSCs were assayed under hypoxic and normoxic conditions in vitro. The results showed that hUCB‐MSCs exhibit higher expression levels of thrombospondin1, pantraxin3, and vascular endothelial growth factor under hypoxic conditions than under normoxic conditions. These results were found to be correlated with our in vivo immunofluorescent staining results. On the basis of these findings, we suggest that hUCB‐MSCs may have a beneficial effect on cerebral ischemia, especially through angiogenesis, neurogenesis, and anti‐inflammatory effects, and thus could be used as a therapeutic agent to treat neurological disorders such as cerebral ischemia. © 2015 Wiley Periodicals, Inc.
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma
Miklóssy, Gabriella, Zhang, Mingming , Chen, Chih-Hong, Hilliard, Tyvette S. , Paladino, David, Choi, Justin Chin-Bong , Kawakami, Joel K., Wongwiwatthananukit, Supakit , Chen, Yuan , Sun, Dianqing , Chang, Leng Chee , Turkson, James , Youn, Ui Joung , Yue, Peibin , Li, Yifei , Sarkaria, Jann N.

Mayo Clinic

Journal of Medicinal Chemistry | September 2, 2015 | Volume: 58 | Issue: 19 | Pages: 7734-7748

10.1021/acs.jmedchem.5b00686 | PMID 26331426 Get It

Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium
Laurent, Louise C. , Abdel‐Mageed, Asim B. , Adelson, P. David , Arango, Jorge , Balaj, Leonora , Breakefield, Xandra O., Carlson, Elizabeth, Majem, Blanca , Chen, Clark C. , Cocucci, Emanuele , Danielson, Kirsty , Courtright, Amanda, Das, Saumya , Enderle, Daniel , Ezrin, Alan M., Galas, David J. , Gandhi, Roopali, Huentelman, Matthew J. , Keuren‐Jensen, Kendall Van , Kalani, Yashar, Kim, Yong , Krichevsky, Anna M. , Lai, Charles Pin‐Kuang , Lal‐Nag, Madhu , Laurent, Clara D., Leonardo, Trevor R. , Malenica, Ivana , Mondal, Debasis , Nejad, Parham, Raffaı̈, Robert L. , Rubio, Renee, Skog, Johan , Spetzler, Robert, Sun, Jie , Tanrıverdi, Kahraman , Vickers, Kasey C. , Wang, Yaoyu, Weiner, Howard L. , Yeri, Ashish, Gould, Stephen J. , Breakefield, Xandra O. , Courtright-Lim, Amanda , Yan, Irene K. , Laurent, Louise C , Carter, Bob S. , Elmageed, Zakaria Y. Abd , Ferrer, Marc , Freedman, Jane E. , Li, Feng , Patel, Tushar , Wang, Liang , Wang, Yaoyu, Wei, Zhiyun , Wong, David T.

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.26533 | PMID 26320937 Get It

Extracellular RNAs (exRNAs) have been identified in all tested biofluids and have been associated with a variety of extracellular vesicles, ribonucleoprotein complexes and lipoprotein complexes. Much of the interest in exRNAs lies in the fact that they may serve as signalling molecules between cells, their potential to serve as biomarkers for prediction and diagnosis of disease and the possibility that exRNAs or the extracellular particles that carry them might be used for therapeutic purposes. Among the most significant bottlenecks to progress in this field is the lack of robust and standardized methods for collection and processing of biofluids, separation of different types of exRNA‐containing particles and isolation and analysis of exRNAs. The Sample and Assay Standards Working Group of the Extracellular RNA Communication Consortium is a group of laboratories funded by the U.S. National Institutes of Health to develop such methods. In our first joint endeavour, we held a series of conference calls and in‐person meetings to survey the methods used among our members, placed them in the context of the current literature and used our findings to identify areas in which the identification of robust methodologies would promote rapid advancements in the exRNA field.
Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4
Matiello, Marcelo , Muralidharan, Rajanandini , Sun, David, Weinshenker, Brian G. , Rabinstein, Alejandro A. , Weinshenker, Brian G

Mayo Clinic

Neurology Genetics | August 27, 2015 | Volume: 1 | Issue: 2 | Pages: No page available

10.1212/nxg.0000000000000013 | PMID 27066556 Get It

There Is Nothing New Under the Sun
Aletti, Giovanni , Bristow, Robert E. , Chi, Dennis, Cliby, William A.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2015 | Volume: 33 | Issue: 30 | Pages: 3520-3520

10.1200/jco.2015.61.9536 | PMID 26304883 Get It

Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques
Monsell, Sarah E. , Kukull, Walter A. , Roher, Alex E., Maarouf, Chera L., Beach, Thomas G. , Caselli, Richard J. , Montine, Thomas J. , Reiman, Eric M. , Serrano, Geidy E.

Mayo Clinic

JAMA Neurology | August 24, 2015 | Volume: 72 | Issue: 10 | Pages: 1124

10.1001/jamaneurol.2015.1721 | PMID 26302353 Get It

REM sleep behavior disorder and neuropathology in Parkinson's disease
Dugger, Brittany N. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Jacobson, Sandra A. , Belden, Christine M. , Sue, Lucia I., Beach, Thomas G. , Driver-Dunckley, Erika, Postuma, Ronald B. , Adler, Charles H. , Sabbagh, Marwan Noel , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Movement Disorders | August 12, 2015 | Volume: 30 | Issue: 10 | Pages: 1413-1417

10.1002/mds.26347 | PMID 26265105 Get It

AbstractIntroductionRapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson's disease (PD) is associated with differences in clinical phenotype, including dementia, autonomic loss, and gait dysfunction. The pathological basis for this remains unclear.MethodsParkinson's disease subjects in a longitudinal clinicopathologic study were screened for probable RBD with the Mayo Sleep Questionnaire. After death, semiquantitative analyses were conducted for synuclein, amyloid, neurofibrillary tangles, and cerebrovascular lesions.ResultsForty cases had probable RBD (PD+RBD), and 41 did not (PD‐RBD). Despite similar age at death (∼80 y) and disease duration (∼14.5 y), PD+RBD had increased synuclein deposition in all regions examined, with nine of 10 regions significantly different. The Lewy body 10‐region total score (scale = 0‐40) was 29.5 in PD+RBD versus 24.5 in PD‐RBD (Cohen‐d effect size = 0.79, P = 0.002). Cerebrovascular lesion burden was slightly higher in PD‐RBD.ConclusionsAlthough overlap occurs between groups, PD patients with probable RBD may have greater density and range of synuclein pathology on autopsy. © 2015 International Parkinson and Movement Disorder Society
Risk and Outcomes of Substance Use Disorder among Anesthesiology Residents
Berge, Keith H., Harman, Ann E., Hanson, Andrew C. , Schroeder, Darrell R. , Warner, David O. , Sun, Huaping, Schroeder, Darrell

Mayo Clinic

Anesthesiology | August 11, 2015 | Volume: 123 | Issue: 4 | Pages: 929-936

10.1097/aln.0000000000000810 | PMID 26263431 Get It

AbstractAbstract In a nested, matched case-cohort design of 384 anesthesia residents who developed substance use disorder (SUD) and 768 controls who did not, receiving medical education in the United States, but not anesthesia knowledge early in residency, was associated with risk of developing SUD. By the end of follow-up, 54 anesthesiology residents (14.1%) with SUD and 10 controls (1.3%) were dead. Those with SUD were 15-, 10-, and 7-fold more likely to not complete residency, to not become board certified, or have adverse medical licensure actions, respectively. Background: The goal of this work is to evaluate selected risk factors and outcomes for substance use disorder (SUD) in physicians enrolled in anesthesiology residencies approved by the Accreditation Council for Graduate Medical Education. Methods: For each of 384 individuals with evidence of SUD while in primary residency training in anesthesiology from 1975 to 2009, two controls (n = 768) who did not develop SUD were identified and matched for sex, age, primary residency program, and program start date. Risk factors evaluated included location of medical school training (United States vs. other) and anesthesia knowledge as assessed by In-Training Examination performance. Outcomes (assessed to December 31, 2013, with a median follow-up time of 12.2 and 15.1 yr for cases and controls, respectively) included mortality and profession-related outcomes. Results: Receiving medical education within the United States, but not performance on the first in-training examination, was associated with an increased risk of developing SUD as a resident. Cases demonstrated a marked increase in the risk of death after training (hazard ratio, 7.9; 95% CI, 3.1 to 20.5), adverse training outcomes including failure to complete residency (odds ratio, 14.9; 95% CI, 9.0 to 24.6) or become board certified (odds ratio, 10.4; 95% CI, 7.0 to 15.5), and adverse medical licensure actions subsequent to residency (hazard ratio, 6.8; 95% CI, 3.8 to 12.2). As of the end of follow-up, 54 cases (14.1%) were deceased compared with 10 controls (1.3%); 28 cases and no controls died during residency. Conclusion: The attributable risk of SUD to several adverse outcomes during and after residency training, including death and adverse medical license actions, is substantial.
Dimensionality Reduction Via Graph Structure Learning
Mao, Qi , Goodison, Steve , Wang, Li , Sun, Yijun

Mayo Clinic

Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining | August 7, 2015 | Volume: No volume available | Issue: No issue available | Pages: 765-774

10.1145/2783258.2783309 Get It